BR9813202A - Processo de administração de genes a células da pele que apresentam antìgenos - Google Patents
Processo de administração de genes a células da pele que apresentam antìgenosInfo
- Publication number
- BR9813202A BR9813202A BR9813202-4A BR9813202A BR9813202A BR 9813202 A BR9813202 A BR 9813202A BR 9813202 A BR9813202 A BR 9813202A BR 9813202 A BR9813202 A BR 9813202A
- Authority
- BR
- Brazil
- Prior art keywords
- antigens
- skin cells
- administration
- genes
- cells
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 210000004927 skin cell Anatomy 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108700005077 Viral Genes Proteins 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
"PROCESSO DE ADMINISTRAçãO DE GENES A CéLULAS DA PELE QUE APRESENTAM ANTìGENOS" Trata-se de um complexo de administração molecular específico a células que apresentam antígenos é formado a partir de um sistema de administração de genes não virais complexado com material genético estranho. O complexo penetra a seguir nas células alvo através de um receptor específico e supera o mecanismo de degradação, de modo que a absorção funcional do material genético estranho, ou transdução, da célula resulte na expressão genética. A invenção também inclui um processo para a imunização gênica sem o emprego de agulhas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5893397P | 1997-09-15 | 1997-09-15 | |
PCT/US1998/019498 WO1999013915A1 (en) | 1997-09-15 | 1998-09-15 | Method of delivering genes to antigen presenting cells of the skin |
Publications (2)
Publication Number | Publication Date |
---|---|
BR9813202A true BR9813202A (pt) | 2000-08-29 |
BR9813202B1 BR9813202B1 (pt) | 2011-11-01 |
Family
ID=22019811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI9813202-4A BR9813202B1 (pt) | 1997-09-15 | 1998-09-15 | complexo de administração de genes; processo de transdução de células com material genético estranho, composição útil para administração de material genético e uso de um complexo de administração de genes. |
Country Status (18)
Country | Link |
---|---|
US (2) | US6420176B1 (pt) |
EP (1) | EP1024836B1 (pt) |
JP (1) | JP2001516729A (pt) |
KR (1) | KR100615117B1 (pt) |
CN (1) | CN100391542C (pt) |
AP (1) | AP1427A (pt) |
AT (1) | ATE347911T1 (pt) |
AU (1) | AU754425B2 (pt) |
BR (1) | BR9813202B1 (pt) |
CA (1) | CA2302316A1 (pt) |
DE (1) | DE69836643T2 (pt) |
EA (1) | EA003832B1 (pt) |
ES (1) | ES2279580T3 (pt) |
IL (2) | IL134842A0 (pt) |
NO (1) | NO327491B1 (pt) |
NZ (1) | NZ503334A (pt) |
OA (1) | OA11612A (pt) |
WO (1) | WO1999013915A1 (pt) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
WO1999013915A1 (en) * | 1997-09-15 | 1999-03-25 | Genetic Immunity, Llc. | Method of delivering genes to antigen presenting cells of the skin |
US20020022034A1 (en) * | 1997-09-15 | 2002-02-21 | Julianna Lisziewicz | Therapeutic DNA vaccination |
AU2669599A (en) * | 1998-02-12 | 1999-08-30 | Regents Of The University Of California, The | Compositions for receptor/liposome mediated transfection and methods of using same |
US7091192B1 (en) * | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
US7375096B1 (en) * | 1998-12-04 | 2008-05-20 | California Institute Of Technology | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network |
US20020006412A1 (en) * | 2000-04-28 | 2002-01-17 | Roberts Bruce L. | Preparation and use of particulates composed of adenovirus particles |
TWI321054B (en) * | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
WO2003012085A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
KR20120104412A (ko) | 2002-09-06 | 2012-09-20 | 인설트 테라페틱스, 인코퍼레이티드 | 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체 |
US8357377B2 (en) * | 2002-10-09 | 2013-01-22 | Suzie Hwang Pun | Cyclodextrin-based materials, compositions and uses related thereto |
WO2004065575A2 (en) * | 2003-01-15 | 2004-08-05 | Research Institute For Genetic And Human Therapy (Right) | Dna compositon and uses thereof |
WO2005056749A2 (en) * | 2003-12-09 | 2005-06-23 | Engeneic Molecular Delivery Pty Ltd. | Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells |
US8586357B2 (en) | 2003-12-23 | 2013-11-19 | Viacyte, Inc. | Markers of definitive endoderm |
WO2005063971A2 (en) | 2003-12-23 | 2005-07-14 | Cythera, Inc | Definitive endoderm |
US8647873B2 (en) | 2004-04-27 | 2014-02-11 | Viacyte, Inc. | PDX1 expressing endoderm |
US7625753B2 (en) | 2003-12-23 | 2009-12-01 | Cythera, Inc. | Expansion of definitive endoderm cells |
US7985585B2 (en) | 2004-07-09 | 2011-07-26 | Viacyte, Inc. | Preprimitive streak and mesendoderm cells |
US20050266554A1 (en) | 2004-04-27 | 2005-12-01 | D Amour Kevin A | PDX1 expressing endoderm |
US7541185B2 (en) | 2003-12-23 | 2009-06-02 | Cythera, Inc. | Methods for identifying factors for differentiating definitive endoderm |
EP2377922B1 (en) | 2004-04-27 | 2020-04-08 | Viacyte, Inc. | PDX1 expressing endoderm |
US7217428B2 (en) * | 2004-05-28 | 2007-05-15 | Technology Innovations Llc | Drug delivery apparatus utilizing cantilever |
US7740861B2 (en) * | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
AU2005272078B2 (en) | 2004-07-09 | 2011-04-14 | Viacyte, Inc. | Methods for identifying factors for differentiating definitive endoderm |
KR20070083559A (ko) | 2004-08-13 | 2007-08-24 | 더 유니버시티 오브 죠지아 리서치 파운데이션, 인코포레이티드 | 인간 배아 줄기세포에서의 자가재생 및 분화를 위한 조성물및 방법 |
BRPI0515332A (pt) * | 2004-09-17 | 2008-07-22 | Univ Massachusetts | composições e seus usos para deficiências das enzimas lisossÈmicas |
KR20060073172A (ko) | 2004-12-24 | 2006-06-28 | 재단법인서울대학교산학협력재단 | 생체 고분자/유전자 복합체 |
BRPI0501037B8 (pt) | 2005-03-18 | 2021-07-27 | Fund De Amparo A Pesquisa Do Estado De Sao Paulo | uso de crotamina e composição |
JP5489462B2 (ja) * | 2005-10-24 | 2014-05-14 | ユニバーシティ オブ マサチューセッツ | 骨病状の遺伝子治療のための組成物およびそれらの使用法 |
EP1957636B1 (en) | 2005-10-27 | 2018-07-04 | Viacyte, Inc. | Pdx1-expressing dorsal and ventral foregut endoderm |
US7695965B2 (en) | 2006-03-02 | 2010-04-13 | Cythera, Inc. | Methods of producing pancreatic hormones |
US11254916B2 (en) | 2006-03-02 | 2022-02-22 | Viacyte, Inc. | Methods of making and using PDX1-positive pancreatic endoderm cells |
DK2650360T3 (da) | 2006-03-02 | 2019-10-07 | Viacyte Inc | Endokrine prekursorceller, pancreatiske hormon udtrykkende celler og fremgangsmåder til fremstilling |
US7989204B2 (en) | 2006-04-28 | 2011-08-02 | Viacyte, Inc. | Hepatocyte lineage cells |
JP2010516625A (ja) | 2007-01-24 | 2010-05-20 | インサート セラピューティクス, インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
US7695963B2 (en) | 2007-09-24 | 2010-04-13 | Cythera, Inc. | Methods for increasing definitive endoderm production |
EP2222283A2 (en) * | 2007-10-29 | 2010-09-01 | University of Massachusetts | Yeast cell wall protein (ycwp) encapsulated multilayered nanoparticles for nucleic acid delivery (sirna) |
WO2009062050A2 (en) | 2007-11-08 | 2009-05-14 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
EP2340309A2 (en) | 2008-09-22 | 2011-07-06 | Rxi Pharmaceuticals Corporation | Neutral nanotransporters |
EP4176888A1 (en) | 2008-11-14 | 2023-05-10 | ViaCyte, Inc. | Encapsulation of pancreatic cells derived from human pluripotent stem cells |
WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
HU0900117D0 (en) | 2009-02-26 | 2009-04-28 | Genetic Immunity Kutatasi | Topical or transdermal delivery kit |
WO2010125544A1 (en) * | 2009-04-30 | 2010-11-04 | Genetic Immunity Kft. | Immunogenic nanomedicine composition and preparation and uses thereof |
EA201200617A1 (ru) * | 2009-11-23 | 2012-11-30 | Серулин Фарма Инк. | Полимеры на основе циклодекстрина для доставки лекарственных средств |
CN103108642B (zh) | 2010-03-24 | 2015-09-23 | 雷克西制药公司 | 皮肤与纤维化症候中的rna干扰 |
WO2011119852A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
TR201807294T4 (tr) | 2010-06-22 | 2018-06-21 | Centre Nat Rech Scient | Nükleik asit konjugatları için endosomolitik ajanlar ile optimize edilmiş in vivo aktarım sistemi. |
AU2015202211B2 (en) * | 2010-06-22 | 2016-09-01 | Centre National De La Recherche Scientifique | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
CN102146416B (zh) * | 2010-12-30 | 2013-03-13 | 江苏大学 | 阳离子化杏鲍菇多糖纳米粒基因传递系统及其制法 |
EP2527440A1 (en) * | 2011-05-27 | 2012-11-28 | Institut Curie | Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia |
WO2014055493A1 (en) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
WO2015024022A2 (en) | 2013-08-16 | 2015-02-19 | University Of Rochester | Designed peptides for tight junction barrier modulation |
EP3188799B1 (en) | 2014-09-05 | 2022-07-06 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1 |
EP3594343B1 (en) | 2015-07-23 | 2021-04-21 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
CN105396140B (zh) * | 2015-12-02 | 2019-07-02 | 浙江医药高等专科学校 | 抗肿瘤免疫治疗纳米给药系统及其构建方法 |
WO2020247347A1 (en) | 2019-06-05 | 2020-12-10 | University Of Rochester | New designed inhibitors of tight junction formation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5620896A (en) * | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
AU2242799A (en) * | 1994-02-22 | 1999-05-27 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
FR2722506B1 (fr) | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
MX9700560A (es) * | 1994-08-05 | 1997-05-31 | Warner Lambert Co | Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales. |
WO1996040265A1 (en) * | 1995-06-07 | 1996-12-19 | The Regents Of The University Of California | Stabilization of polynucleotide complexes |
DE19605279A1 (de) * | 1996-02-13 | 1997-08-14 | Hoechst Ag | Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung |
EP0882134B8 (en) * | 1996-02-21 | 2009-09-02 | Genetic Immunity kft. | Methods and compositions for protective and therapeutic genetic immunization |
FR2747046B1 (fr) * | 1996-04-05 | 1998-06-19 | Univ Paris Curie | Nouveaux vaccins issus de plasmovirus |
WO1999013915A1 (en) * | 1997-09-15 | 1999-03-25 | Genetic Immunity, Llc. | Method of delivering genes to antigen presenting cells of the skin |
-
1998
- 1998-09-15 WO PCT/US1998/019498 patent/WO1999013915A1/en active IP Right Grant
- 1998-09-15 OA OA1200000074A patent/OA11612A/en unknown
- 1998-09-15 EA EA200000325A patent/EA003832B1/ru not_active IP Right Cessation
- 1998-09-15 ES ES98947128T patent/ES2279580T3/es not_active Expired - Lifetime
- 1998-09-15 IL IL13484298A patent/IL134842A0/xx active IP Right Grant
- 1998-09-15 NZ NZ503334A patent/NZ503334A/en unknown
- 1998-09-15 US US09/153,198 patent/US6420176B1/en not_active Expired - Fee Related
- 1998-09-15 AU AU93980/98A patent/AU754425B2/en not_active Ceased
- 1998-09-15 KR KR1020007002661A patent/KR100615117B1/ko not_active IP Right Cessation
- 1998-09-15 CN CNB988111675A patent/CN100391542C/zh not_active Expired - Fee Related
- 1998-09-15 AP APAP/P/2000/001762A patent/AP1427A/en active
- 1998-09-15 CA CA002302316A patent/CA2302316A1/en not_active Abandoned
- 1998-09-15 AT AT98947128T patent/ATE347911T1/de not_active IP Right Cessation
- 1998-09-15 JP JP2000511529A patent/JP2001516729A/ja active Pending
- 1998-09-15 EP EP98947128A patent/EP1024836B1/en not_active Expired - Lifetime
- 1998-09-15 BR BRPI9813202-4A patent/BR9813202B1/pt not_active IP Right Cessation
- 1998-09-15 DE DE69836643T patent/DE69836643T2/de not_active Expired - Lifetime
-
2000
- 2000-03-01 IL IL134842A patent/IL134842A/en not_active IP Right Cessation
- 2000-03-09 NO NO20001244A patent/NO327491B1/no not_active IP Right Cessation
-
2002
- 2002-02-21 US US10/081,922 patent/US7910562B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
IL134842A (en) | 2009-02-11 |
ATE347911T1 (de) | 2007-01-15 |
US6420176B1 (en) | 2002-07-16 |
KR20010030598A (ko) | 2001-04-16 |
EP1024836B1 (en) | 2006-12-13 |
AU9398098A (en) | 1999-04-05 |
US20020193333A1 (en) | 2002-12-19 |
NZ503334A (en) | 2002-05-31 |
BR9813202B1 (pt) | 2011-11-01 |
NO20001244D0 (no) | 2000-03-09 |
OA11612A (en) | 2004-08-13 |
EP1024836A4 (en) | 2003-07-02 |
DE69836643D1 (de) | 2007-01-25 |
AP1427A (en) | 2005-06-07 |
CN1278739A (zh) | 2001-01-03 |
AU754425B2 (en) | 2002-11-14 |
AP2000001762A0 (en) | 2000-03-31 |
US7910562B2 (en) | 2011-03-22 |
CN100391542C (zh) | 2008-06-04 |
DE69836643T2 (de) | 2007-09-27 |
CA2302316A1 (en) | 1999-03-25 |
EP1024836A1 (en) | 2000-08-09 |
JP2001516729A (ja) | 2001-10-02 |
EA003832B1 (ru) | 2003-10-30 |
KR100615117B1 (ko) | 2006-08-22 |
ES2279580T3 (es) | 2007-08-16 |
NO327491B1 (no) | 2009-07-20 |
NO20001244L (no) | 2000-05-15 |
IL134842A0 (en) | 2001-05-20 |
WO1999013915A1 (en) | 1999-03-25 |
EA200000325A1 (ru) | 2000-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9813202A (pt) | Processo de administração de genes a células da pele que apresentam antìgenos | |
Hassan et al. | Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue | |
Ross et al. | Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links | |
Carlton et al. | Peripheral GABAA receptors: evidence for peripheral primary afferent depolarization | |
Shelhamer et al. | Immunologic and neuropharmacologic stimulation of mucous glycoprotein release from human airways in vitro | |
BR0012069A (pt) | Composições e métodos para a terapia e diagnóstico de câncer pulmonar | |
AU705924B2 (en) | Botulinum toxin derivatives able to modify peripheral sensory afferent functions | |
BR9912007A (pt) | Composições e métodos para terapia e diagnóstico de câncer de próstata | |
Sluka et al. | Spinal projections of the locus coeruleus and the nucleus subcoeruleus in the Harlan and the Sasco Sprague-Dawley rat | |
BR0010648A (pt) | Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril | |
BR0009537A (pt) | Composições para tratamento e diagnóstico de câncer de mama e métodos para seu uso | |
BR0210579A (pt) | Anticorpos, cadeias pesadas e leves, composição farmacêutica e métodos de detecção do nìvel de opgl em amostra biológia e de tratamento | |
BRPI0113477B8 (pt) | proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula | |
ES2155074T3 (es) | Adenovirus que comprende fibras penton fusionadas a peptidos que alterna la especificidad de union para celulas blanco. | |
BR9608558A (pt) | Processos e usos de fator de crescimento de tecido conjuntivo como um agente de indução | |
ATE368054T1 (de) | Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität | |
WO1998007850A3 (en) | Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans | |
Colin et al. | In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogenous basic fibroblast growth factor | |
HUP9800028A2 (hu) | Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének | |
Lee et al. | Stimulation by epinephrine of in vivo phosphorylation and inactivation of acetyl coenzyme A carboxylase of rat epididymal adipose tissue. | |
BR0110091A (pt) | Composições e processos para terapia e diagnóstico de câncer de mama | |
Inaishi et al. | Cooperative regulation of calcitonin gene-related peptide levels in rat sensory neurons via their central and peripheral processes | |
KR900701302A (ko) | 암치료를 위한 신규의 고친화성 변형된 항체군 | |
MX9801264A (es) | Control de la expresion del gen de cd44 para uso terapeutico. | |
Marshall et al. | Recovery of function after mesotelencephalic dopaminergic injury in senescence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/11/2011, OBSERVADAS AS CONDICOES LEGAIS. |
|
B24H | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi) | ||
B24F | Patent annual fee: publication cancelled |
Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE AS 14A, 15A, 16A, 17A, 18A, 19A, 20A, 21A E 22A ANUIDADES. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2607 DE 22-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |